| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Mikus, MS, et al.
(författare)
-
Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation
- 2022
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 59:2
-
Tidskriftsartikel (refereegranskat)abstract
- Asthma phenotyping requires novel biomarker discovery.ObjectivesTo identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of severe (SA) and mild-to-moderate (MMA) asthmatics, COPD subjects and healthy controls (HCs).MethodsAn antibody-based array targeting 177 proteins predominantly involved in pathways relevant to inflammation, lipid metabolism, signal transduction and extracellular matrix was applied to plasma from 525 asthmatics and HCs in the U-BIOPRED cohort, and 142 subjects with asthma and COPD from the validation cohort BIOAIR. Effects of oral corticosteroids (OCS) were determined by a 2-week, placebo-controlled OCS trial in BIOAIR, and confirmed by relation to objective OCS measures in U-BIOPRED.ResultsIn U-BIOPRED, 110 proteins were significantly different, mostly elevated, in SA compared to MMA and HCs. 10 proteins were elevated in SA versus MMA in both U-BIOPRED and BIOAIR (alpha-1-antichymotrypsin, apolipoprotein-E, complement component 9, complement factor I, macrophage inflammatory protein-3, interleukin-6, sphingomyelin phosphodiesterase 3, TNF receptor superfamily member 11a, transforming growth factor-β and glutathione S-transferase). OCS treatment decreased most proteins, yet differences between SA and MMA remained following correction for OCS use. Consensus clustering of U-BIOPRED protein data yielded six clusters associated with asthma control, quality of life, blood neutrophils, high-sensitivity C-reactive protein and body mass index, but not Type-2 inflammatory biomarkers. The mast cell specific enzyme carboxypeptidase A3 was one major contributor to cluster differentiation.ConclusionsThe plasma proteomic panel revealed previously unexplored yet potentially useful Type-2-independent biomarkers and validated several proteins with established involvement in the pathophysiology of SA.
|
|
| 5. |
|
|
| 6. |
- Reinke, SN, et al.
(författare)
-
Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study
- 2022
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 59:6
-
Tidskriftsartikel (refereegranskat)abstract
- Asthma is a heterogeneous disease with poorly defined phenotypes. Patients with severe asthma often receive multiple treatments including oral corticosteroids (OCS). Treatment may modify the observed metabotype, rendering it challenging to investigate underlying disease mechanisms. Here, we aimed to identify dysregulated metabolic processes in relation to asthma severity and medication.MethodsBaseline urine was collected prospectively from healthy participants (n=100), patients with mild-to-moderate asthma (n=87) and patients with severe asthma (n=418) in the cross-sectional U-BIOPRED cohort; 12–18-month longitudinal samples were collected from patients with severe asthma (n=305). Metabolomics data were acquired using high-resolution mass spectrometry and analysed using univariate and multivariate methods.ResultsA total of 90 metabolites were identified, with 40 significantly altered (p<0.05, false discovery rate <0.05) in severe asthma and 23 by OCS use. Multivariate modelling showed that observed metabotypes in healthy participants and patients with mild-to-moderate asthma differed significantly from those in patients with severe asthma (p=2.6×10−20), OCS-treated asthmatic patients differed significantly from non-treated patients (p=9.5×10−4), and longitudinal metabotypes demonstrated temporal stability. Carnitine levels evidenced the strongest OCS-independent decrease in severe asthma. Reduced carnitine levels were associated with mitochondrial dysfunction via decreases in pathway enrichment scores of fatty acid metabolism and reduced expression of the carnitine transporter SLC22A5 in sputum and bronchial brushings.ConclusionsThis is the first large-scale study to delineate disease- and OCS-associated metabolic differences in asthma. The widespread associations with different therapies upon the observed metabotypes demonstrate the need to evaluate potential modulating effects on a treatment- and metabolite-specific basis. Altered carnitine metabolism is a potentially actionable therapeutic target that is independent of OCS treatment, highlighting the role of mitochondrial dysfunction in severe asthma.
|
|
| 7. |
|
|
| 8. |
- Fernandes, SJ, et al.
(författare)
-
Deep characterization of paired chromatin and transcriptomes in four immune cell types from multiple sclerosis patients
- 2021
-
Ingår i: Epigenomics. - : Future Medicine Ltd. - 1750-192X .- 1750-1911. ; 13:20, s. 1607-1618
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The putative involvement of chromatin states in multiple sclerosis (MS) is thus far unclear. Here we determined the association of chromatin-accessibility with concurrent genetic, epigenetic and transcriptional events. Material & methods: We generated paired assay for transposase-accessible chromatin sequencing and RNA-sequencing profiles from sorted blood immune CD4+ and CD8+ T cells, CD14+ monocytes and CD19+ B cells from healthy controls (HCs) and MS patients. Results: We identified differentially accessible regions between MS patients and HCs, primarily in CD4+ and CD19+. CD4+ regions were enriched for MS-associated single nucleotide polymorphisms and differentially methylated loci. In the vicinity of differentially accessible regions of CD4+ cells, 42 differentially expressed genes were identified. The top two dysregulated genes identified in this multilayer analysis were CCDC114 and SERTAD1. Conclusion: These findings provide new insight into the primary role of CD4+ and CD19+ cells in MS.
|
|
| 9. |
|
|
| 10. |
- Gudowski, Waclaw, et al.
(författare)
-
Review of the European project - Impact of Accelerator-Based Technologies on Nuclear Fission Safety (IABAT)
- 2001
-
Ingår i: Progress in nuclear energy (New series). - 0149-1970 .- 1878-4224. ; 38:1-2, s. 135-151
-
Tidskriftsartikel (refereegranskat)abstract
- The IABAT project - Impact of Accelerator Based Technologies on Nuclear Fission Safety - started in 1996 in the frame of 4(th) Framework Programme of the European Union, R&D specific programme Nuclear fission safety 1994-1998, area A.2 Exploring innovative approaches/Fuel cycle concepts, as one of the first common European activities in ADS. The project was completed October 31, 1999. The overall objective of the IABAT project has been a preliminary assessment of the potential of Accelerator-Driven Systems (ADS) for transmutation of nuclear waste and for nuclear energy production with minimum waste generation. Moreover, more specific topics related to nuclear data and code development for ADS have been studied in more detail. Four ADSs have been studied for different fuel/coolant combinations: liquid metal coolant and solid fuel, liquid metal coolant and dispersed fuel, and fast and thermal molten salt systems. Target studies comprised multiple target solutions and radiation damage problems in a target environment. In a tool development part of the project a methodology of subcriticality monitoring has been developed based on Feynman-alpha and Rossi-alpha methods. Moreover, a new Monte-Carlo burnup code taking full advantage of continuous neutron cross-section data has been developed and benchmarked. Impact on the risk from high-level waste repositories fi om radiotoxicity reduction using ADS has been assessed giving no crystal-clear benefits of ADS for repository radiotoxicity reduction but concluding some important prerequisites for effective transmutation. In proliferation studies important differences between critical reactors and ADS have been underlined and non-proliferation measures have been proposed. In assessment of accelerator technology costing models have been created that allow the circular and linear accelerator options to be compared and the effect of parameter variations examined. The calculations reported show that cyclotron systems would be more economical, due mainly to the advantage of the cost of RF power supplies. However, the accelerator community regards with skepticism the possibility of transporting and extracting more than a 10mA beam current from a 1GeV cyclotron and therefore technical factors may limit the application of cyclotrons. Finally, this review summarizes development of nuclear data in the energy region between 20 Mev and 150 MeV. Neutron and proton transport data files for Fe, Ni, Pb, Th, U-238 and Pu-239 have been created. The high-energy part of the data files consists completely of results from model calculations, which are benchmarked against the available experimental data. Although there is obviously future work left regarding fine-tuning of several parts of the data files, the representation of nuclear reaction information up to 150 MeV is already better than can be attained with intranuclear cascade codes.
|
|
